Fruquintinib
Colorectal Cancer
Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Jiangsu Cancer Institute & Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07622550CT.gov A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance | — | Not Yet Recruiting | — | — | — |
NCT07502014CT.gov A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07591597CT.gov A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07515820CT.gov SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study | — | Not Yet Recruiting | — | — | — |
NCT07124858CT.gov Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07483684CT.gov A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs | — | Not Yet Recruiting | — | — | — |
NCT07446465CT.gov FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07384377CT.gov JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | — | Not Yet Recruiting | — | — | — |
NCT07362836CT.gov Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) | — | Not Yet Recruiting | — | — | — |
NCT07353268CT.gov Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. | — | Not Yet Recruiting | — | — | — |
Show 72 more trialsShow fewer
NCT07235293CT.gov A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | — | Recruiting | — | — | — |
NCT07286695CT.gov Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07150403CT.gov Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07229872CT.gov A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment | — | Not Yet Recruiting | — | — | — |
NCT06856837CT.gov - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | — | Recruiting | — | — | — |
NCT06992258CT.gov A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07011576CT.gov A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | — | Recruiting | — | — | — |
NCT07136077CT.gov A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT07051785CT.gov Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT05690035CT.gov Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer | — | Withdrawn | — | — | — |
NCT07003022CT.gov Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC | — | Recruiting | — | — | — |
NCT06985316CT.gov An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations. | — | Not Yet Recruiting | — | — | — |
NCT06470178CT.gov A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents | — | Not Yet Recruiting | — | — | — |
NCT06980532CT.gov Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06746545CT.gov A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer. | — | Not Yet Recruiting | — | — | — |
NCT06979908CT.gov A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06562543CT.gov A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | — | Recruiting | — | — | — |
NCT06497985CT.gov A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT06551207CT.gov Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | — | Recruiting | — | — | — |
NCT06484153CT.gov Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06218888CT.gov A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT06441565CT.gov Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | — | Recruiting | — | — | — |
NCT06255379CT.gov Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06423937CT.gov Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06356597CT.gov Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial | — | Active Not Recruiting | — | — | — |
NCT06347198CT.gov Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06356584CT.gov Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases | — | Recruiting | — | — | — |
NCT06199973CT.gov Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan | — | Active Not Recruiting | — | — | — |
NCT06543836CT.gov ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer | — | Recruiting | — | — | — |
NCT06010888CT.gov Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC | — | Unknown | — | — | — |
NCT06118762CT.gov Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06099314CT.gov Fruquintinib in the Cross-line Treatment of Refractory mCRC | — | Unknown | — | — | — |
NCT05993702CT.gov TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05954429CT.gov A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | — | Recruiting | — | — | — |
NCT05571644CT.gov Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT07491159CT.gov Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study | — | Active Not Recruiting | — | — | — |
NCT06168786CT.gov Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | — | Recruiting | — | — | — |
NCT05555901CT.gov The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05771181CT.gov Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT05747716CT.gov SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC | — | Not Yet Recruiting | — | — | — |
NCT05661357CT.gov Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression | — | Unknown | — | — | — |
NCT05659290CT.gov Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05634590CT.gov The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05565417CT.gov Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05447715CT.gov Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05279677CT.gov FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage | — | Unknown | — | — | — |
NCT05522738CT.gov Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05435313CT.gov Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | — | Unknown | — | — | — |
NCT05451719CT.gov Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | — | Unknown | — | — | — |
NCT05016869CT.gov Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05004831CT.gov Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC | — | Unknown | — | — | — |
NCT05368805CT.gov Fruquintinib DDI Study With P-gp and BCRP Substrates | — | Completed | — | — | — |
NCT05511051CT.gov A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | — | Unknown | — | — | — |
NCT04866108CT.gov A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy | — | Unknown | — | — | — |
NCT04948034CT.gov The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | — | Unknown | — | — | — |
NCT04577963CT.gov A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05004441CT.gov Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04733963CT.gov Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04296019CT.gov Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06202417CT.gov Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study | — | Completed | — | — | — |
NCT05025631CT.gov A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） | — | Completed | — | — | — |
NCT04695470CT.gov Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients | — | Unknown | — | — | — |
NCT04322539CT.gov A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04446091CT.gov A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) | — | Unknown | — | — | — |
NCT04431791CT.gov Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer | — | Unknown | — | — | — |
NCT06221423CT.gov Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04179084CT.gov Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer | — | Unknown | — | — | — |
NCT03977090CT.gov Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06011330CT.gov Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02314819CT.gov A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) | — | Completed | — | — | — |
NCT02196688CT.gov Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01975077CT.gov A Phase Ib Study of Fruquintinib in 3rd Line mCRC | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fruquintinib (this asset) | Jiangsu Cancer Institute & Hospital | Approved | BB · 67 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Fruquintinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastasis From Malignant Tumor Of Colon | — | P3 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Fruquintinib in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fruquintinib-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →